Drug Profile
Research programme: toll-like receptor-mediated inflammatory disease therapy - Opsona/Wyeth
Latest Information Update: 15 Sep 2011
Price :
$50
*
At a glance
- Originator Opsona Therapeutics; Wyeth
- Class
- Mechanism of Action Toll-like receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Autoimmune disorders; Inflammation
Most Recent Events
- 15 Sep 2011 Discontinued for Autoimmune disorders in Ireland (unspecified route)
- 15 Sep 2011 Discontinued for Inflammation in Ireland (unspecified route)
- 15 Oct 2009 Wyeth has been acquired by Pfizer